SignalCorporate
Lilly outlines $91B-$92B 2026 revenue outlook as Medicare GLP-1 Bridge and Foundayo rollout expand access
Lilly's $91B–$92B 2026 revenue outlook cites Medicare GLP-1 Bridge and Foundayo rollout expanding access.
Context
What happened: Eli Lilly outlined a 2026 revenue outlook and cited the Medicare GLP-1 Bridge and Foundayo rollout as expanding access, while reporting Q3 2026 results and raising full year guidance.
Key numbers: 2026 revenue outlook of $91B to $92B.
Why it matters: Management described Q3 as another quarter of solid execution, with raised full year guidance, pipeline progress and an expanded manufacturing footprint.
What changed
Eli Lilly outlined a 2026 revenue outlook and cited the Medicare GLP-1 Bridge and Foundayo rollout as expanding access, while reporting Q3 2026 results and raising full year guidance.
Why it matters
Management described Q3 as another quarter of solid execution, with raised full year guidance, pipeline progress and an expanded manufacturing footprint.